Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy
- Conditions
- Pain Due to Certain Specified ProceduresNeuropathic Pain
- Interventions
- Other: PLACEBO
- Registration Number
- NCT01325090
- Lead Sponsor
- University Hospital, Limoges
- Brief Summary
Botulinum toxin type A has been reported to inhibit the release of various pain neurotransmitters (SP, CGRP, glutamate) responsible for neurogenic inflammation, a process that results from the sensitization of C-fiber nociceptors (peripheral sensitization). This action is probably responsible for the analgesic effect of botulinum toxin type A recently demonstrated in patients with neuropathic pain of peripheral origin.In those studies, patients had been suffering for years. The investigators can hypothesizes that earlier administration of Botox in the course of neuropathic pain might prevent central sensitization, that is secondary to peripheral sensitization. The investigators can hope to increase efficacy of Botulinum toxin type A injections and to prevent chronification of pain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- daily pain, for 3 months, secondary to thoracoscopy or thoracotomy, of neuropathic origin (DN4 questionary)
- contraindications for botulinum toxin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BOTOX BOTOX Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area PLACEBO PLACEBO Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
- Primary Outcome Measures
Name Time Method decrease in average pain intensity as measured by the Brief Pain Inventory (BPI) one month
- Secondary Outcome Measures
Name Time Method VAS in the last 24 hours 24 hours Neuropathic Pain Inventory 6 months